What Can You Expect in 2026?
The Industry’s Premier Conference for End-to-End Oligonucleotide Analytical Development & CMC Excellence
With the rapid expansion of oligonucleotide therapeutics across ASOs, siRNA, gRNA, and increasingly complex conjugates, the demand on analytical development and CMC teams to stay ahead of evolving molecular complexity and regulatory expectations has never been greater.
With increasing scrutiny on impurity characterization, control strategy justification, raw material quality, and comparability across synthesis platforms, the need for robust, scalable, and analytically driven CMC strategies for oligonucleotide therapeutics has never been more critical.
As the industry’s definitive and end-to-end oligonucleotide AD & CMC forum, the 5th Oligonucleotide Analytical Development & CMC Summit returns to Boston, bringing together analytical, CMC and regulatory leaders to define the roadmap for successful oligo development. Showcasing analytical development, impurity profiling, CMC strategy, quality, GMP, process development, formulation, stability and regulatory perspectives, the 2026 program is designed to empower drug developers like yourself to confidently characterise, control and scale high quality oligonucleotide therapeutics towards approval.
Join the industry’s only dedicated community for oligonucleotide analytical development and CMC excellence, where 90+ technical leaders, regulators, and innovators unite to define best practices, benchmark strategies, and accelerate the delivery of safe, high quality oligonucleotide therapeutics to patients.
Event Highlights
Key Focus Areas Include:
Regulatory & CMC Excellence
Navigating emerging EMA draft guidance, evolving global regulatory expectations, and defining robust control strategies to ensure analytical comparability, justify impurity thresholds, and enable successful regulatory submissions
Characterizing Increasingly Complex Oligonucleotide Modalities
Tackling analytical challenges associated with conjugated oligonucleotides, highly modified chemistries, and novel backbones, with deep dives into structural characterization, higher-order structure, and orthogonal analytical approaches
Advancing Analytical Technologies to Inform CMC Strategy
Discover how leading companies are leveraging advanced LC-MS, HILIC, NMR, and emerging analytical platforms to improve impurity identification, enhance sensitivity, and drive more informed, data-driven CMC decision making
From Impurity Profiling to Proactive Control Strategies
Master how to move beyond detection towards building robust, phase-appropriate control strategies, linking analytical insights to process understanding to ensure consistency, scalability, and product quality from early to late-stage development
Book Your Free 1:1 Agenda Consultation
Connect with our dedicated team member to review the agenda, explore the speakers, and identify the sessions most relevant to your role and company.
Erica Kamweti
Delegate Audience Manager
Explore the Full Event Guide
- 90+ Oligo Experts sharing end‑to‑end analytical development & CMC strategies
- 15+ Case Studies spanning AD, CMC, digitization, characterization, and more
- 11 Core Themes including impurity profiling, analytical tech, synthesis scale‑up, comparability, regulatory guidance & complex chemistries
- 8+ Hours of Networking with global pharma, biotech, regulatory & analytical leaders
- 2 New Workshops on impurity profiling & regulatory deep‑dive
Attending Companies Include
Explore the Agenda
Dive into cutting-edge Oligonucleotide Analytical Development & CMC strategies that will become your blueprint to high quality, safe, and cost-effective Oligo production across all modalities.
Partner With Us
Showcase your technologies and services to decision-makers actively seeking the tools to advance next-generation Oligonucleotide therapies.
Join Biopharma Experts
Be part of the only forum uniting leading pharma, biotech, academia, and regulatory experts.